Sertraline HCl belongs to a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). Sertraline HCl has the same mechanism of action as other SSRIs. It works by increasing the amount of serotonin that is available in the brain. Serotonin is a neurotransmitter, or chemical messenger, that is involved in regulating many elements of a person’s daily life, including mood, sleep, rewards, learning, and memory. Research has linked depression with low levels of serotonin. Sertraline increases the amount of serotonin present in the brain, helping to reduce chemical imbalances and improve a person’s overall mood. Sertraline is available as either an oral tablet or a liquid. Typically, a person takes a dose in the morning or evening, once a day. People using it to treat premenstrual dysphoric disorder may take it every day or only on select days of the month.
Market Dynamics
Key trends in the market include increasing prescription rate and expenditure for antidepressant drug which is expected to drive the market growth during the forecast period. For instance, according to an article published in Springer Nature Switzerland AG in March 2021, stated that the total number of Ads (antidepressants) prescriptions dispensed during COVID-19 pandemic (January to December 2020) were 78 million, 4 million more than in 2019 that costed the National Health Service (NHS) is the publicly funded healthcare system in England, £139 million (US $170.7 million) more than in 2019. Sertraline, an SSRI antidepressant drug, alone accounted for an extra £113 million (US $ 138.7 million) during 2020 than in 2019.
Key features of the study:
- This report provides an in-depth analysis of the global sertraline HCl market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global sertraline HCl market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
- Key companies covered as a part of this study include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Accord Biopharma, Apotex Inc., Aurobindo Pharma USA, InvaGen, Lupin, Camber Pharmaceuticals, Mylan (a part of Viatris Inc.), Sun Pharmaceutical, Wockhardt, Alpic Biotech
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global sertraline HCl market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global sertraline HCl market.
Detailed Segmentation:
- Global Sertraline HCl Market, By Type:
- 25 mg
- 50 mg
- 100 mg
- Others
- Global Sertraline HCl Market, By Application:
- Obsessive-Compulsive Disorder
- Depression
- Panic Disorder
- Premenstrual Dysphoric Disorder
- Others
- Global Sertraline HCl Market, By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Sertraline HCl Market, By Region:
- North America
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Country
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Pfizer Inc *
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.,
- Novartis AG
- Accord Biopharma
- Apotex Inc.,
- Aurobindo Pharma USA
- InvaGen
- Lupin
- Camber Pharmaceuticals
- Mylan N.V. (a part of Viatris Inc.)
- Sun Pharmaceutical
- Wockhardt
- Alpic Biotech
“*” marked represents similar segmentation in other categories in the respective section.
